Physician profile
Andre Fedida
NPI 1891839312
$3,272.85
in general payments reported to CMS, 2019-2025
24 companies · $516 in 2025
The $516 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $343 · 2020: $200 · 2021: $258 · 2022: $567 · 2023: $488 · 2024: $900 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,864 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,864.37 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $614.82 | 2019-2024 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $310.77 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $307.57 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Celgene Corporation | $294.47 | 2022-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $293.18 | 2019-2023 | Linzess |
| Pfizer INC. | $246.12 | 2019-2025 | |
| Abbvie INC. | $235.63 | 2019-2025 | |
| Redhill Biopharma INC. | $183.12 | 2021-2024 | Talicia, Aemcolo, Movantik |
| Phathom Pharmaceuticals, INC. | $167.73 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $140.26 | 2019-2024 | |
| Madrigal Pharmaceuticals | $123.15 | 2024-2025 | Rezdiffra, Resmetirom |
| Novo Nordisk INC | $78.68 | 2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $38.77 | 2020-2022 | |
| Genzyme Corporation | $36.13 | 2024-2025 | |
| Allergan, INC. | $35.36 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $27.89 | 2022-2023 | Dificid |
| Alfasigma USA, INC. | $26.22 | 2022 | |
| Fujifilm Healthcare Americas Corporation | $20.91 | 2020 | |
| Celltrion USA INC. | $17.76 | 2024 | Vegzelma |
| Vivus LLC | $17.54 | 2024 | Qsymia |
| Ferring Pharmaceuticals INC. | $14.97 | 2023 | Rebyota |
| Aimmune Therapeutics, INC. | $14.10 | 2024 | |
| Alnylam Pharmaceuticals INC. | $13.94 | 2020 | |
| Nestle Healthcare Nutrition INC. | $13.76 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andre Fedida listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.